Physician profile
Deya Alkhatib
NPI 1942725544
$6,858.16
in general payments reported to CMS, 2019-2025
18 companies · $2,761 in 2025
The $2,761 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $170 · 2021: $230 · 2023: $1,606 · 2024: $2,091 · 2025: $2,761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,539 · Travel and Lodging: $2,521 · Grant: $1,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,538.52 |
| Travel and Lodging | $2,521.05 |
| Grant | $1,398.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,216.66 | 2023-2025 | Triclip, Mitraclip, Amplatzer Amulet |
| Boston Scientific Corporation | $1,456.98 | 2023-2025 | General - Therapies |
| E.R. Squibb & Sons, L.L.C. | $375.29 | 2023-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $306.05 | 2023-2025 | Azure Xt Dr Mri Surescan, Cobalt Dr Mri Surescan |
| Nuwellis, INC. | $266.68 | 2024 | Aquadex Smartflow Console |
| Astrazeneca Pharmaceuticals Lp | $170.06 | 2020 | |
| Edwards Lifesciences Corporation | $167.41 | 2025 | Pascal |
| Stryker Corporation | $125.83 | 2025 | Flowtriever |
| Alnylam Pharmaceuticals INC. | $125.00 | 2024 | Amvuttra |
| Penumbra, INC. | $120.22 | 2021 | |
| Heartflow, INC. | $110.53 | 2025 | |
| Ns Pharma, INC. | $110.13 | 2021 | |
| Pfizer INC. | $99.79 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $85.84 | 2025 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $50.96 | 2024 | Arcalyst |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $27.40 | 2025 | |
| Recor Medical INC | $25.48 | 2025 | Paradise Ultrasound Renal Denervation System |
| Lantheus Medical Imaging, INC. | $17.85 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deya Alkhatib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.